HAVCR2 and neoplasm: The anti-Tim-3 antibody has been tested clinically as a new addition to immune checkpoint blockade immunotherapies [57,58,59], although the mechanism underlying how Tim-3 blockade achieves its anti-tumor effects is not well understood [60].